Dr. Mark A. Socinski is a medical oncologist and Executive Director of the AdventHealth Cancer Institute in Orlando, Florida. He specializes in thoracic malignancies including pleural mesothelioma and non-small and small cell lung cancers and is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for those diseases.
Education and Career
Dr. Socinski earned his medical degree at the University of Vermont Medical School in Burlington, Vermont, and then completed his internship and residency in Internal Medicine at Beth Israel Hospital/Harvard Medical School. He completed his medical training in Medical Oncology at the Dana-Farber Cancer Institute/Harvard Medical School. 
Before being named Executive Medical Director of the Florida Hospital Cancer Institute, Dr. Socinski served as Director of the Multidisciplinary Thoracic Oncology Program at the University of North Carolina and Professor of Medicine and Cardiovascular Surgery; Director of the Lung Cancer Section for the Division of Hematology and Oncology; Co-director of the Lung Cancer Center of Excellence; and Co-director of the Lung Cancer Program at the University of Pittsburgh Medical Center (UPMC) Cancer Pavilion.
Professional Memberships and Associations
Dr. Socinski is an active member of many professional societies including The American College of Physicians, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He also serves as co-chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance).
Dr. Socinski’s research focuses on treating lung cancer through the delivery of personalized medicine based on molecular biomarkers. As Executive Medical Director of the AdventHealth Cancer Institute, he has played a significant role in the development of numerous cooperative clinical trials.
Dr. Socinski’s recent publications include:
- Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. CLINICAL CANCER RESEARCH 2023
- Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. The oncologist 2023
- Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA ONCOLOGY 2023
- Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine. FRONTIERS IN ONCOLOGY 2023
- IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. JOURNAL OF THORACIC ONCOLOGY 2023
- [‘Poziotinib in Non-Small-Cell Lung Cancer Harboring’, ‘Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.’]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2022
- A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer. EXPERT OPINION ON INVESTIGATIONAL DRUGS 2022
- Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. NATURE MEDICINE 2022